Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 135 participants.
Also called NCT01458405
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 135 participants
- Sponsor
- Registry
-
NCT01458405
-
- Other papers using this trial's data
- Effect of cardiosphere-derived cells on segmental myocardial function after myocardial infarction: ALLSTAR randomised clinical trial
- Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT01458405. Randomized; triple masking; primary purpose treatment. Start 2012-11-13 (actual); primary completion 2017-07-03 (actual). Results posted on 2024-04-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
- Acronym
- ALLSTAR
- Condition
- Myocardial Infarction
- Intervention (Biological)
- CAP-1002 Allogeneic Cardiosphere-Derived Cells
- Intervention (Drug)
- Placebo
- Lead sponsor
- Capricor Inc.
- Collaborator
- National Institutes of Health (NIH)
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator
- California Institute for Regenerative Medicine (CIRM)
Record details
- Record id
cardio:ct-nct01458405- Content hash
ee7950ec077edd3a6f6cdb027663e59cc6409e89ffa7ac8c93478f73493c1dfe